tbuckley/cabot-search huggingface dataset:
Role of Na,K-ATPase in regulating acidification of early rat liver endocytic vesicles, ,
Authors: M Anbari
Journal: Hepatology (1994)

Endocytic vesicles are acidified by an electrogenic proton pump and a parallel chloride conductance; however, acidification might be decreased if electrogenic transporters, such as Na,K-ATPase, that increase vesicle interior-positive membrane potential were also present.We examined this issue in early rat liver endosomes using ion substitution and inhibitors to alter Na,K-ATPase activity.These early endosomes, labeled for 2 min with the fluorescent fluid-phase marker fluorescein isothiocyanate-dextran, consistently acidified faster than endosomes similarily labeled for a 10-min period.In chloride-free media initial rates of acidification of early endosomes were faster in K + media than in Na+ medium, although addition of K + to Na+ or Na+ to K+ media to allow Na,K-ATPase to function did not decrease the rate of acidification.In chloride-containing media, rates were the same regardless of cation composition.The Na,K-ATPase inhibitor vanadate was prepared from orthovanadate by several methods, all of which inhibited liver ATPase activity.Two hundred pmol/L vanadate, prepared C1-free, tended to decrease rates of acidification in all media tested and these effects achieved statistical significance in Cl--free media containing 150 mmoln K+ or mixtures of Na+ and K+ and in 145 mmol/L KC1/5 mmol/L NaCl medium.Vanadate stocks pH-adjusted with hydrogen chloride increased rates of acidification in sodium gluconate buffers, probably as a result of the effects of the included C1-.Five mmol/L ouabain (loaded into vesicles by endocytosis) and the membrane-permeable analog strophanthidin (2 mmol/L) both markedly inhibited endosome acidification, regardless of buffer ion composition.Collectively, these results suggest that Na,K-ATPase does not regulate acidification of rat liver early endocytic vesicles, that
Drug development, regulation, and the practice of medicine
Authors: W. M. Wardell
Journal: JAMA (1974)

IN LESS than five decades, the "pharmaceutical revolution" has transformed therapeutics. The purpose of this report is to propose and examine the hypothesis that the process by which drugs are now developed and regulated has become a prototype for wider changes in the structure of medical practice. <h3>Patients, Physicians, Government, and Industry</h3> Before therapeutic drugs achieved their present economic importance, such development of useful new therapies as did occur (eg, quinine, digitalis, morphine, hypnotics, local and general anesthetics, cholinergics and anticholinergics, amyl nitrite, anthelmintics, antiscorbutics, hormones, and vitamins) stemmed mainly from the academic and professional communities. The main change of the past 50 years is the nearly total transfer of the responsibility for developing new drugs to the pharmaceutical industry, supervised by government. Industry's participation developed because of the enormous increase in the cost and complexity of drug development,<sup>1</sup>and because of the profitability of the process. Government's entry
Creighton University Marks Centennial
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Withdrawn
Authors: Gina Coscia, Matthew Perzanowski, Hannah Smith, Chanelle Ryan, Paul Planet, Young-Chan Kim, Boram Bae, Sungmi Choi, Kyoung-Hee Sohn, Hye Park, Min-Gyu Kang, Min-Suk Yang, Jae-Woo Jung, Sang Lee, Sae-Hoon Kim, Sang-Heon Cho, Hana Yi, Hye- Ryun Kang
Journal: Journal of Allergy and Clinical Immunology (2018)
Phenytoin Hypersensitivity
Authors: Alan J. Wilensky
Journal: JAMA (1977)

<h3>To the Editor.—</h3> Drs Michael and Mitch (236:2773-2775, 1976) described a patient who "was given phenytoin and phenobarbital but no other medications." Three weeks later a skin rash developed, and the patient was advised to stop taking the medications. Six days following that she was admitted to a hospital, at which time neither phenytoin or phenobarbital were detected in her serum. In this patient, a syndrome of exfoliative dermatitis, hepatitis, fever, lymphadenopathy, renal failure, and myositis later developed. The authors state that the illness was "presumably caused by phenytoin hypersensitivity." Phenobarbital is not mentioned in the article except in the case report. Although this syndrome could have been caused by phenytoin hypersensitivity, it could also have been the result of phenobarbital hypersensitivity. Since shortly after phenobarbital was introduced, it has been known that this drug could produce cutaneous reactions. In severe cases, this can proceed to a syndrome of fever,
Abstract 2928: New insight into signaling contexts for the administration of the imipridone ONC201 to prostate cancer cells
Authors: Francesca Amoroso, Adam Pickard, Kimberly Glass, Rohinton Tarapore, Josh Allen, Ian G. Mills
Journal: Cancer Research (2019)

Abstract Prostate cancer is the most common non-cutaneous cancer in men and a notable cause of cancer mortality. In the majority of the cases localised disease radical treatment consists of surgery or radiotherapy. Upon progression androgen deprivation therapy can extend survival however metastatic disease is incurable. The prostate is a specialized accessory gland with a high secretory capacity. As prostate cancer develops and treatment resistance emerges, the unfolded protein response (UPR) is an important adaptive biology which co-amplifies with key cancer drivers1. The UPR can be cytoprotective but when acutely activated can lead to cell death. In this study we sought to enhance the acute activation of the UPR using radiation and ONC201, previously reported to be a UPR activator2. We found that treating prostate cancer cells with ONC201 induced increases in the expression of components in all arms of the UPR - ATF4, ATF6 and IRE1-XBP1 - at protein and transcript levels at a 24-hour time point and this was followed at 72 hours by cell death. This delay in the induction of cell death provided a time window for the short-term administration of ONC201 to prime an enhanced cytotoxic response to radiation. Pre-treatment with ONC201 for 24 hours followed by withdrawal and subsequent irradiation led to enhanced cytotoxicity assessed by cell viability and clonogenic assays. In order to decipher the impact of ONC201 and radiation we undertook RNA-seq under a range of treatment conditions. We noted a durable suppression of transcripts encoding cell cycle regulatory genes when ONC201 pre-treatment was used to enhance radiation response and this translated into cell cycle arrest and induction of both necrotic and apoptotic cell death as assessed by flow cytometry. Pathway analysis of the RNA-seq suggests alternative targets that could replicate this priming effect to enhance radiation response. 1.Storm, M. et al., Oncotarget 7(33): 54051-54066 (2016). 2.Allen, J. et al., Oncotarget (2016). doi:10.18632/oncotarget.11814. Citation Format: Francesca Amoroso, Adam Pickard, Kimberly Glass, Rohinton Tarapore, Josh Allen, Ian G. Mills. New insight into signaling contexts for the administration of the imipridone ONC201 to prostate cancer cells [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 2928.
Demonstration of the feasibility of two innovative models of HCV testing and treatment in two unique populations in Punjab and Delhi, India-head-start project, India
Authors: Sonjelle Shilton, Gagandeep Singh Grover, Ekta Gupta, Sundeep Miglani, Radha Krishan Dhiman, Dr. Manpreet Chhatwal, Preetishirin Katapur, Navneet Tewatia, Mugil Murya, Pradeep Sangwan, Divya Soni, Jessica Markby, Sanjay Sarin, Babu Entoor Ramachandran
Journal: Journal of Hepatology (2020)
Device infections: Clinical outcome following early device reimplantation Steven P. Chough, Christian Sticherling, Robert L. Baker, Kristina Wasmer, Hiroshi Tada, Chi-Wo Chan, Radmira Greenstein, Hakan Oral, Frank Pelosi, Jr., Bradley P. Knight, Fred Morady, Adam Strickberger. University of Michigan Medical Center, Ann Arbor, MI
Journal: Journal of the American College of Cardiology (2001)
External Cardiac Compression
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Tobacco Industry and the Brown and Williamson Documents-Reply
Authors: Lisa Bero
Journal: JAMA (1996)

<h3>In Reply.</h3> —As discussed in our article, Mantel's<sup>1</sup>criticisms (published some months later) were used by the Tobacco Institute to conduct a massive public relations campaign criticizing Hirayama's article.<sup>2</sup>The point made in our article was that the Tobacco Institute launched this campaign even though some of its consultants, including Dr Lee, had stated that they disagreed with Mantel's analysis. Lee confirms in his letter that he did not agree with Mantel's criticisms of the statistics used in Hirayama's article, which is consistent with our interpretation of the historical record. We did not mean to suggest that Dr Sterling's advisory group was designed to influence the content of the 1967 DHEW report, "Cigarette Smoking and Health Characteristics." The advisory group was established to influence future government reports. Sterling's statement, "No attempts were or could be made to influence the publication of the government public policy document," misses the
Transfusion Therapy
Authors: M. Fragoso
Journal: CA A Cancer Journal for Clinicians (1986)

radiation isdone before releasing theblood products fortransfusion.The units ofblood products are prominently labeled as irra diated.We findno particular disadvantage in transfusing irradiated bloodproducts since our population of recipients isclearly de fined.Irradiated blood components do not pose any potential for radiation exposure topatients or personnel who handlethem.Ifordersforan irradiated blood product arecancelled, itisreleased fortransfusion tootherpatients.
Abstract 3852: Development of1,2-bis(hydroxymethyl)benzo[g]pyrrolo[2,1-a]phthalazine hybrids as potent anticancer agents to small cell lung cancer
Authors: Tai-Lin Chen, Vicky Jain, Yi-Wen Lin, Tsann-Long Su, Te-Chang Lee
Journal: Cancer Research (2019)

Abstract Angiogenesis is a hallmark of cancer development, especially in lung cancer and colorectal cancer. Unfortunately, the rapid development of resistance to anti-angiogenesis agents has limited the clinical benefits for the treatment. To improve the efficacy of anti-angiogenesis agents, we designed and synthesized a series of new hybrid molecules that are composed of benzophthalazine (anti-angiogenesis moiety) and bis(hydroxymethyl)pyrrole (DNA interstrand crosslinking moiety). We demonstrate that these compounds are the dual function inducing DNA crosslinking and anti-angiogenesis. 1,2-Bis(hydroxymethyl)benzopyrrolo[2,1-a]phthalazine derivatives displayed potent cytotoxicity to leukemia and a batch of solid tumor cell lines. Among them, small cell lung cancer (SCLC) cells were the most susceptible cells with the IC50 values ranged from dozens of nanomolar to submicromolar. Significantly, we observed total tumor remission by treatment of SCLC H526 (TP53 WT) xenografts with formulated compound 8 at the dose of 20mg/kg, 5 times/week for 2 weeks. In addition, compound 8 was also more potent than cisplatin in suppression of growth of SCLC H211 (TP53 mutant) xenografts. Combination treatment of H211 cells with compound 8 and cisplatin displayed the synergistically cell killing. Our preliminary results further showed that co-treatment of compound 8 and low dose cisplatin significantly suppressed tumor growth and prolonged the survival rate of mice bearing H211 xenografts. In contract to cisplatin, treatment of mice with compound 8 did not cause body weight lost, indicating low systematic toxicity of compound 8. In summary, our results indicate that bis(hydroxymethyl)benzopyrrolo[2,1-a]phthalazine hybrids, either alone or in combination with other therapeutic drugs, are potent anticancer agents against SCLC and deserve for future development. Note: This abstract was not presented at the meeting. Citation Format: Tai-Lin Chen, Vicky Jain, Yi-Wen Lin, Tsann-Long Su, Te-Chang Lee. Development of1,2-bis(hydroxymethyl)benzo[g]pyrrolo[2,1-a]phthalazine hybrids as potent anticancer agents to small cell lung cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3852.
Highlights
Journal: JAMA (2014)

Varespladib and Cardiovascular Events in Patients With ACS 252Secretory phospholipase A 2 (sPLA 2 ) generates phospholipid products implicated in atherosclerosis.Nicholls and colleagues assessed the effects of varespladib-an sPLA 2 inhibitor-on cardiovascular outcomes in a multicenter trial involving 5145 patients who were randomly assigned to 16 weeks' treatment with varespladib or placebo within 96 hours of presentation with an acute coronary syndrome (ACS).The authors found that varespladib did not reduce the risk of recurrent cardiovascular events and significantly increased the risk of myocardial infarction. CEA and CT Follow-up to Detect Colorectal Cancer Recurrence 263In a randomized trial that enrolled 1202 patients who had undergone treatment for primary colorectal cancer, Primrose and colleagues evaluated the efficacy of scheduled carcinoembryonic antigen (CEA) assessment and computed tomography (CT)-separately or combined-to detect recurrent, treatable disease during 5 years' follow-up.The authors report that compared with minimum follow-up-a single CT examination if requested by the hospital clinician-CT or CEA screening each improved colorectal cancer recurrence detection, but combining the 2 strategies offered no additional benefit.
Ca̧o Gío (Coin Rubbing)
Authors: Gentry W. Yeatman
Journal: JAMA (1980)

<i>Ca̧o gío</i>is the Vietnamese practice of rubbing the skin with a coin to alleviate various common symptoms of illness. The back, neck, head, shoulders, and chest are common sites of application. Although mimicking the lesions of trauma, it is not a harmful procedure, and no complications are known. A survey of 50 Vietnamese living in the United States since 1975 and 1976 has shown marked distrust of American physicians, owing largely to actual or perceived criticism of<i>ca̧o gío</i>. Acceptance of<i>ca̧o gío</i>as a valid cultural practice will facilitate compliance and adequate medical follow-up. (<i>JAMA</i>1980;244:2748-2749)
Bahrain unrest
Authors: R. Sollom, V. Iacopino
Journal: BMJ (2011)

Breaches principles of medical neutrality and international law Wang Bo/Xinhau Press/CORBIS Thousands of protesters in the small island Kingdom of Bahrain in the Persian Gulf took to the streets calling for government reform in early 2011. The government’s response was brutal and systematic: shoot civilian protesters, detain and torture them, and erase all evidence. On the frontline, treating hundreds of these wounded civilians, doctors had firsthand knowledge of these abuses and suffered from them themselves. Physicians for Human Rights and Médecins Sans Frontières each reported on these attacks against medical personnel, which were the result of their efforts to provide neutral care to wounded pro-democracy demonstrators⇑. On 22 April a report by Physicians for Human Rights documented violations of well established principles of medical neutrality (box).1 #### Violations of principles of medical neutrality by the Bahraini authorities1
Prisoners of Metaphor
Journal: JAMA (1970)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AUTHOR'S REPLY
Authors: P. Burney
Journal: Thorax (1988)

Why study the epidemiology of asthma?Dr Peter Burney (June 1988;43:425-8) was right to insist that epidemiological research is as necessary in the elucidation of the pathogenesis of asthma as study of the underlying mechanisms.More questionable, however, is his confidence that it will pay good dividends, for up to now epidemiology's contribution to our understanding of asthma has been disappointingly small.'Improvement will come only when it
MEDICAL AID TO LABRADOR.
Journal: JAMA (1894)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sleep
Authors: W. Ross Adey
Journal: JAMA (1966)

<b>Sleep,</b>by Ian Oswald, 141 pp, with illus, paper, 950, Baltimore: Penguin Books, 1966. The last traditional stronghold of personal privacy, the bedroom, has seen its bastions fall to the insatiable curiosity of physiological investigators, and its proprieties have been made the common stock of glossy magazines. Apart from shallow titillation of vicarious fancy, there has grown a popular interest in sleep and sleep mechanisms. Two recent publications, each bearing the simple title,<i>Sleep</i>, have recently appeared. While each one aims at a popular presentation, they are interestingly different as they reveal personal impressions of sleep research —in one case by intelligent laymen, and in the other by a renowned sleep researcher. The volume by Luce and Segal is a smoothly written and sensitive account of the authors' visits to sleep research laboratories in New York, Chicago, Los Angeles, and Stanford. To those who have passed endless nights in constant